Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma

Jemal, 2005, Contemporary lung cancer trends among U.S. women, Cancer Epidemiol Biomarkers Prev, 14, 582, 10.1158/1055-9965.EPI-04-0554 Kessler, 2003, The natural history of prostate cancer, Urol Clin North Am, 30, 219, 10.1016/S0094-0143(02)00182-9 Jenster, 1999, The role of the androgen receptor in the development and progression of prostate cancer, Semin Oncol, 26, 407 Sunday, 1988, Gastrin-releasing peptide gene expression in developing, hyperplastic, and neoplastic human thyroid C-cells, Endocrinology, 122, 1551, 10.1210/endo-122-4-1551 Guo, 2000, Roles of gastrointestinal hormones in pancreatic cancer, J Hepatobiliary Pancreat Surg, 7, 276, 10.1007/s005340070049 Scott, 2004, Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours, J Clin Pathol, 57, 189, 10.1136/jcp.2003.10660 Glover, 2003, Increased frequency of gastrin-releasing peptide receptor gene mutations during colon-adenocarcinoma progression, Mol Carcinog, 37, 5, 10.1002/mc.10117 Scopinaro, 2002, Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients, Cancer Biother Radiopharm, 17, 327, 10.1089/10849780260179297 Sun, 2000, Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers, Prostate, 42, 295, 10.1002/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B Williams, 1994, Bombesin receptors in a human duodenal tumor cell line: binding properties and function, Cancer Res, 54, 818 Chung, 1992, Bombesin stimulates growth of human gastrinoma, Surgery, 112, 1059 Bologna, 1989, Bombesin stimulates growth of human prostatic cancer cells in vitro, Cancer, 63, 1714, 10.1002/1097-0142(19900501)63:9<1714::AID-CNCR2820630912>3.0.CO;2-H Aprikian, 1998, Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer, Prostate Suppl, 8, 52, 10.1002/(SICI)1097-0045(1998)8+<52::AID-PROS9>3.0.CO;2-I Jongsma, 2000, Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines, Prostate, 42, 34, 10.1002/(SICI)1097-0045(20000101)42:1<34::AID-PROS5>3.0.CO;2-2 Koppan, 1998, Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma, Cancer, 83, 1335, 10.1002/(SICI)1097-0142(19981001)83:7<1335::AID-CNCR10>3.0.CO;2-5 Szepeshazi, 1999, Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs, J Cancer Res Clin Oncol, 125, 444, 10.1007/s004320050301 Zhou, 2004, Targeting gastrin-releasing peptide receptors for cancer treatment, Anticancer Drugs, 15, 921, 10.1097/00001813-200411000-00001 Schally, 2004, Chemotherapy targeted to cancers through tumoral hormone receptors, Trends Endocrinol Metab, 15, 300, 10.1016/j.tem.2004.07.002 Smith, 2003, Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update, Nucl Med Biol, 30, 861, 10.1016/S0969-8051(03)00116-1 Scheffel, 2004, PET imaging of GRP receptor expression in prostate cancer, J Nucl Med, 45, 1277 Varvarigou, 2004, Gastrin-releasing peptide (GRP) analogues for cancer imaging, Cancer Biother Radiopharm, 19, 219, 10.1089/108497804323072002 Van de Wiele, 2001, Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging?, Nucl Med Commun, 22, 5, 10.1097/00006231-200101000-00002 Krenning, 2004, Peptide receptor radionuclide therapy, Ann N Y Acad Sci, 1014, 234, 10.1196/annals.1294.026 Maecke, 2005, 68Ga-labeled peptides in tumor imaging, J Nucl Med, 46, 172S Van de Wiele, 2001, Biodistribution and dosimetry of 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies, J Nucl Med, 42, 1722 Van de Wiele, 2000, Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study, Eur J Nucl Med, 27, 1694, 10.1007/s002590000355 Shao, 1997, Simultaneous PET and MR imaging, Phys Med Biol, 42, 1965, 10.1088/0031-9155/42/10/010 Schuhmacher, 2005, GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog, J Nucl Med, 46, 691 Chen, 2004, MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts, J Nucl Med, 45, 1390 Rogers, 2003, MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue, Bioconjug Chem, 14, 756, 10.1021/bc034018l McCarthy, 1997, Efficient production of high specific activity 64Cu using a biomedical cyclotron, Nucl Med Biol, 24, 35, 10.1016/S0969-8051(96)00157-6 Lewis, 1999, Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model, Clin Cancer Res, 5, 3608 Rogers, 2004, In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate, Cancer Biother Radiopharm, 19, 25, 10.1089/108497804773391649 Yaghoubi, 2001, Human pharmacokinetic and dosimetry studies of [18F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression, J Nucl Med, 42, 1225 Schoder, 2004, Positron emission tomography for prostate, bladder, and renal cancer, Semin Nucl Med, 34, 274, 10.1053/j.semnuclmed.2004.06.004 Kwee, 2005, Prostate cancer localization with 18fluorine fluorocholine positron emission tomography, J Urol, 173, 252, 10.1097/01.ju.0000142099.80156.85 Yamaguchi, 2005, Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy, Eur J Nucl Med Mol Imaging, 32, 742, 10.1007/s00259-004-1755-y Seltzer, 2004, Radiation dose estimates in humans for 11C-acetate whole-body PET, J Nucl Med, 45, 1233 Boswell, 2004, Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes, J Med Chem, 47, 1465, 10.1021/jm030383m Sprague, 2004, Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator, Clin Cancer Res, 10, 8674, 10.1158/1078-0432.CCR-04-1084 Wong, 2000, Synthesis and characterization of cross-bridged cyclams and pendant-armed derivatives and structural studies of their copper(II) complexes, J Am Chem Soc, 122, 10561, 10.1021/ja001295j Sun, 2002, Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands, J Med Chem, 45, 469, 10.1021/jm0103817